Sugi Predict

Sugi Predict / Compounds / Heptylformamide

Heptylformamide

Heptylformamide

SCHEMBL146004

CCCCCCCNC=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 6/20 1.00
▸ ADH1B P00325 4/20 1.00
▸ ADH1A P07327 4/20 1.00
▸ ADH7 P40394 4/20 1.00
▸ ADH1C P00326 3/20 1.00
▸ ADH4 P08319 2/20 1.00
▸ TSHR P16473 3/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ FAAH O00519 2/20 0.48
▸ TRPV1 Q8NER1 1/20 0.48
▸ S1PR2 O95136 2/20 0.45
▸ S1PR4 O95977 2/20 0.45
▸ S1PR1 P21453 2/20 0.45
▸ S1PR3 Q99500 2/20 0.45
▸ ZDHHC20 Q5W0Z9 1/20 0.45
▸ ZDHHC2 Q9UIJ5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303653 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL145544 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL9660807 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL9661679 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL302735 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL9661848 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL58363 1.00 — —
SCHEMBL9658779 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL4879688 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL305123 1.00 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 712 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641827-A The method of catalytic production formic acid and catalyst used in the process of regenerating this under low over-voltage OXFA有限公司 2019-04-16 — — CN claimed
CN-109641828-A Method for separating formic acid from reaction mixture by extraction OXFA有限公司 2019-04-16 — — CN claimed
EP-1790639-B1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2014-03-26 — — EP claimed
US-8344142-B2 perylenetetracarboxylic diimide core having side chains (groups or mesogens) attached to the core; to provide charge-transport materials having various volatilities, solubilities, crystallinity, and charge transport ability; organic light emitting diode; photovoltaic cells, light-emitting diodes GEORGIA TECH RESEARCH CORPORATION (US) 2013-01-01 — — US claimed
US-8039625-B2 Coronene charge-transport materials, methods of fabrication thereof, and methods of use thereof GEORGIA TECH RESEARCH CORPORATION (US) 2011-10-18 — — US claimed
US-7951816-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2011-05-31 — — US claimed
CN-100551902-C light active material ROLIC AG (CH) 2009-10-21 — — CN claimed
US-20090044863-A1 CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF NATIONAL SCIENCE FOUNDATION 2009-02-19 — — US claimed
US-20080223444-A1 Perylene Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof GEORGIA TECH RESEARCH CORPORATION 2008-09-18 — — US claimed
US-7163933-B2 Treating agent for Paget's disease of bone TEIJIN LIMITED (JP) 2007-01-16 — — US claimed
EP-1342796-A2 Compound for the treatment of paget's disease of bone TEIJIN LIMITED (JP) 2003-09-10 — — EP claimed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 — — EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 — — US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 — — WO claimed
EP-0527049-B1 Quinophthalone compound MITSUI CHEMICALS INC (JP) 1998-12-23 — — EP claimed
EP-0457195-B1 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1998-04-15 — — EP claimed
US-5656604-A HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 — — US claimed
US-5430022-A Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-07-04 — — US claimed
US-5284828-A Hypotensive agents FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 1994-02-08 — — US claimed
EP-0457195-A2 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-21 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080223444-A1 Perylene Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof SLC43A1, SLC3A2, SLC16A3 EPHX1 2731/4885ADH1B 1391/4885ADH1A 1792/4885
US-20090044863-A1 CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF SLC18A3, CORO1C, SLC18A1 EPHX1 3018/4885ADH1B 1551/4885ADH1A 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.